Moderna (NASDAQ: MRNA) faces significant challenges as analysts downgrade ratings amidst revised revenue forecasts. With a delayed break-even point and cuts to R&D spending, the biotech firm is positioned for a tough road ahead. Cautious traders should watch closely for updates.